Zealand Total Debt

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>ZP</div>
ZEAL -- Denmark Stock  

DKK 241.40  3.60  1.47%

Zealand Pharma total debt fundamental analysis lookup allows you to check this and other indicators for Zealand Pharma AS or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Total Debt

 
Refresh
Long Term Debt to Equity is projected to rize to 0.30 this year.

Zealand Total Debt Analysis

Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
 2019 2020 (projected)
Long Term Debt to Equity0.2893910.297006
Interest Coverage54.2853.96
Zealand Pharma AS, a biotechnology company, engages in the discovery and development of peptide based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 191 people.
Total Debt 
 = 
Bonds 
+  
Notes 
More About Total Debt | All Equity Analysis

Current Zealand Pharma AS Total Debt

101.21 M

Zealand Distress Driver Correlations

About Total Debt

In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Compare to competition

Zealand Pharma Total Debt Related Assessment

  Long Term Debt to Equity

Based on latest financial disclosure Zealand Pharma AS has Total Debt of 101.21 M. This is 96.32% lower than that of the Healthcare sector, and 68.84% lower than that of Biotechnology industry, The Total Debt for all stocks is 98.1% higher than the company.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Zealand PharmaCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee1.49 M1.71 M1.89 M1.09 M254.88 K293.11 K300.82 K
PPandE Turnover7.9510.715.569.42.392.752.82
Receivables Turnover6.831.862.546.432.282.632.7
Return on Investment(17.485101)(14.919921)(19.674061)(38.659417)73.2865.9571.16
Cash Flow Per Share(1.864127)(9.475695)1.6(9.08349)(14.985709)(17.233565)(17.68708)
Revenue to Assets0.2576820.29570.3379920.1895930.0308810.0355130.036447
Quick Ratio7.478.323.899.1110.2711.8112.13
Receivables34.95 M167.23 M16.89 M26.61 M6.64 M5.98 M6.14 M
Accounts Payable18.49 M21.68 M19.74 M29.43 M32.65 M29.39 M31.71 M
Direct Expenses13.78 M22.27 M31.46 M14.63 M3.36 M3.02 M3.1 M

Zealand Fundamentals

About Zealand Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Zealand Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zealand Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zealand Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.

Current Sentiment - ZEAL

Zealand Pharma AS Investor Sentiment

Macroaxis portfolio users are unemotional in their take regarding investing in Zealand Pharma AS. What is your take regarding investing in Zealand Pharma AS? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Also Currentnly Active

<div class='circular--portrait-small' style='font-weight: 700;background:#FF0F00;color: #FFFFF0;font-size:1.1em;padding-top: 10px;;'>CI</div>
Purchased over 60 shares of
few hours ago
Traded for 44.1
<div class='circular--portrait-small' style='font-weight: 700;background:#347AFC;color: #ffffff;font-size:0.9em;padding-top: 12px;;'>VMW</div>
Purchased over 20 shares of
few hours ago
Traded for 134.6
<div class='circular--portrait-small' style='font-weight: 700;background:#4E8BFC;color: #ffffff;font-size:1.1em;padding-top: 10px;;'>SA</div>
Purchased few shares of
few hours ago
Traded for 177.85
Check out Zealand Pharma Piotroski F Score and Zealand Pharma Altman Z Score analysis. Please also try Instant Ratings module to determine any equity ratings based on digital recommendations. macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page